PRecision Oncology CUhk pRogrammE (PRO-CURE)

Status Recruiting

Clinical Trial Summary

The main aim of this project is to establish an innovative model of a comprehensive precision oncology platform to help individualizing drug therapy for patients with advanced cancers at The Chinese University of Hong Kong. The other objectives include to optimize the genomic matching and access of patients with unique cancer subtypes to the relevant clinical trials of novel therapies, and to construct a personalized drug screening platform for individuals using novel cancer models established from patient-derived cancer cells and tissues. Other objectives include to investigate the utility and feasibility of genomic sequencing using circulating tumor DNA(ctDNA), and to establish a biobank of tumor tissues derived from patients with unique cancer subtypes.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04724070
Study type	Observational
Source	Chinese University of Hong Kong
Contact	Brigette MA, MD
Phone	22939871
Email	brigette@clo.cuhk.edu.hk
Status	Recruiting
Phase
Start date	October 16, 2019
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02349958` - Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy	Phase 2
Completed	`NCT00585637` - Vitamin D for Chemoprevention	Phase 1
Terminated	`NCT02005614` - A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection	N/A
Completed	`NCT00364078` - Transitoriness in Cancer Patients, Psychosocial Issues in Cancer Care	N/A
Withdrawn	`NCT05359042` - Electronic Patient Reported Outcomes in Patients With Gastrointestinal Cancers	N/A
Terminated	`NCT03407040` - Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapy
Completed	`NCT02045368` - Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R	Phase 1
Completed	`NCT01200121` - Bevacizumab as a Palliative Treatment for Patients With Symptomatic Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers	Phase 2
Recruiting	`NCT02013089` - A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study	N/A
Recruiting	`NCT05641896` - Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers	Phase 2